Improved Treatment for Metastatic Castrate-Sensitive Prostate Cancer

Posted by jime51 @jime51, May 31 8:31pm

Here's an article discussing improved progression-free survival with the use of combined medications, including enzalutamide. https://www.medpagetoday.com/meetingcoverage/asco/121512

Interested in more discussions like this? Go to the Prostate Cancer Support Group.

northoftheborder | @northoftheborder | Jun 1 12:18pm

Good to have further confirmation that adding a PARP inhibitor to doublet therapy is helpful when the patient has metastatic castrate-sensitive prostate cancer with the BRCA1/2 mutations. Things are getting better and better.

(Note that this trial applies only to the minority of prostate cancer patients who have those genetic mutations.)